Clinical trials: Ulcerative Colitis, Active Moderate
Mild to Moderately Active Ulcerative Colitis
Pilot Study of Green Tea Extract (Polyphenon E®)in Ulcerative Colitis
Green tea consists of several components, with most research focusing on the polyphenol fraction. The polyphenol fraction(-)-epigallocatechin-3-gallate (EGCG)has been studied extensively as an anti-inflammatory agent as well as a…
- Trial name
- NCT00718094
- Testing
- Polyphenon E®
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Louisville
Colitis, Ulcerative
BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis
To evaluate the long-term safety of BI 655130 (SPESOLIMAB) in patients with moderate to severely active ulcerative colitis, who have completed treatment in previous trials To evaluate the long-term efficacy of BI 655130…
- Trial name
- NCT03648541
- Testing
- Spesolimab
- Where
- 38 sites in United States, Austria and 10 more
- Volunteers
- 79 people
- Sponsor
- Boehringer Ingelheim
Ulcerative Colitis
Pharmacokinetics of Adalimumab With Methotrexate for Treatment of Patients With Ulcerative Colitis (UC)
Assess the body's reaction to dose-response relationship for the adalimumab/Methotrexate interaction in subjects with moderately to severely active ulcerative colitis.
- Trial name
- NCT01716039
- Testing
- MTX 12.5, MTX 25, Adalimumab
- Volunteers
- 22 people
- Sponsor
- Alimentiv Inc.
Colitis, Ulcerative
Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis
The purpose of this study is to investigate the efficacy and safety of vedolizumab intravenous (IV) dose optimization on mucosal healing compared with the standard vedolizumab IV dosing regimen over a 30 week treatment period in…
- Trial name
- ENTERPRET (NCT03029143)
- Testing
- Vedolizumab IV
- Where
- 49 sites in United States, Canada
- Volunteers
- 278 people
- Sponsor
- Takeda
Ulcerative Colitis
Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).
- Trial name
- NCT05570006
- Testing
- ABBV-668
- Where
- 30 sites in United States, Belgium and 2 more
- Volunteers
- 30 people
- Sponsor
- AbbVie
Ulcerative Colitis
A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to evaluate the efficacy and safety of mirikizumab as maintenance therapy in participants who completed as clinical responders in the prior 12-week induction study LUCENT-1 (NCT03518086).
- Trial name
- LUCENT 2 (NCT03524092)
- Testing
- Mirikizumab SC, Mirikizumab IV
- Where
- 385 sites in United States, Argentina and 32 more
- Volunteers
- 1,328 people
- Sponsor
- Eli Lilly and Company
Ulcerative Colitis
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of vixarelimab compared with placebo in participants with moderate to severe UC who have demonstrated inadequate response to, loss of…
- Trial name
- NCT06137183
- Testing
- Vixarelimab
- Where
- 65 sites in United States, Brazil and 10 more
- Volunteers
- 79 people
- Sponsor
- Genentech, Inc.
Ulcerative Colitis
Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis
The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for moderately active ulcerative colitis in adult participants.
- Trial name
- GLADIATOR UC (NCT04607837)
- Testing
- Etrasimod
- Where
- 288 sites in United States, Australia and 16 more
- Volunteers
- 234 people
- Sponsor
- Pfizer
Ulcerative Colitis
A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis.
The proposed study is a randomized, double-blind,placebo-controlled, multicenter phase II study to investigate the safety and efficacy of SHR0302 in patients with moderate to severe active ulcerative colitis.
- Trial name
- NCT03675477
- Testing
- SHR0302
- Where
- 67 sites in United States, China and 3 more
- Volunteers
- 164 people
- Sponsor
- Reistone Biopharma Company Limited
Ulcerative Colitis
CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Ulcerative Colitis (LIBERTY-UC)
This is Phase 3, Randomized, Placebo-controlled study to demonstrate superiority of CT-P13 SC over Placebo SC in Patients With Moderately to Severely Active Ulcerative Colitis
- Trial name
- NCT04205643
- Testing
- CT-P13 SC (Infliximab)
- Where
- Poland
- Volunteers
- 548 people
- Sponsor
- Celltrion
Ulcerative Colitis
A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis
This study is designed to evaluate the efficacy and safety of tofacitinib (CP-690,550) in patients with moderate to severe ulcerative colitis who have failed or be intolerant to one of following treatments for ulcerative colitis…
- Trial name
- OCTAVE (NCT01458951)
- Testing
- tofacitinib
- Where
- 182 sites in United States, Australia and 27 more
- Volunteers
- 547 people
- Sponsor
- Pfizer
Active Ulcerative Colitis
A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis
The primary objective of the study is to evaluate the clinical activity of interferon beta-1a in participants with moderate to severe ulcerative colitis (UC).
- Trial name
- NCT00616434
- Testing
- BG9418 (Interferon beta-1a)
- Where
- 35 sites in United States, Canada and 5 more
- Volunteers
- 123 people
- Sponsor
- Biogen
Ulcerative Colitis, Digestive System Diseases
Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis
The purpose of this study is to determine the safety and tolerability of administration of multiple ascending doses of KHK4083 and to select the highest dose tolerated by subjects with moderately active Ulcerative Colitis (UC)…
- Conditions
- Ulcerative Colitis, Digestive System Diseases, Colitis, Ulcerative, Colitis
- Trial name
- NCT02647866
- Testing
- KHK4083
- Where
- 23 sites in United States, Czechia and 5 more
- Volunteers
- 66 people
- Sponsor
- Kyowa Kirin, Inc.
Ulcerative Colitis
Efficacy, Pharmacodynamics, Safety and Tolerability of Oral BL-7040 in Patients With Moderately Active Ulcerative Colitis
The objective of the proposed study is to determine whether BL-7040 demonstrates clinical efficacy in patients with inflammatory bowel disease (IBD).
- Trial name
- NCT01506362
- Testing
- BL-7040
- Where
- 5 sites in Israel
- Volunteers
- 22 people
- Sponsor
- BioLineRx, Ltd.
Ulcerative Colitis
A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis
A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Study to Assess Efficacy and Safety of SER-287 in Adults with Active Mild-to-Moderate Ulcerative Colitis
- Trial name
- ECO-RESET (NCT03759041)
- Testing
- Vancomycin Pre-Treatment, SER-287
- Where
- 93 sites in United States, Canada
- Volunteers
- 203 people
- Sponsor
- Seres Therapeutics, Inc.
Ulcerative Colitis (UC)
A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
This study was comprised of three substudies. The objective of Substudy 1 was to characterize the dose-response, efficacy, and safety of upadacitinib compared to placebo in inducing clinical remission to identify the induction…
- Trial name
- NCT02819635
- Testing
- Upadacitinib
- Where
- 496 sites in United States, Argentina and 44 more
- Volunteers
- 1,302 people
- Sponsor
- AbbVie
Colitis, Ulcerative
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
The purpose of this study is to assess the effects (good and bad) of golimumab (CNTO 148) therapy in participants with active ulcerative colitis (UC) (sores in the colon).
- Trial name
- NCT00488774
- Testing
- Golimumab 1 mg per kg, Golimumab 2 mg per kg, Golimumab 4 mg per kg
- Where
- 108 sites in United States, Australia and 20 more
- Volunteers
- 291 people
- Sponsor
- Janssen Research & Development, LLC
Ulcerative Colitis
(CB-01-02/02) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis
This will be a multicentre, randomised, double-blind, double-dummy, parallel group comparative study in patients with mild or moderate, active ulcerative colitis.
- Trial name
- NCT00679380
- Testing
- Blood sampling, endoscopy, Budesonide MMX® 6 mg, Budesonide MMX® 9 mg
- Where
- 71 sites in Australia, Belgium and 13 more
- Volunteers
- 514 people
- Sponsor
- Bausch Health Americas, Inc.
Ulcerative Colitis
A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)
The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with moderately to severely active Ulcerative Colitis (UC).
- Trial name
- ARTEMIS-UC (NCT04996797)
- Testing
- Tulisokibart, Companion Diagnostic (CDx) Testing
- Where
- 88 sites in United States, Australia and 10 more
- Volunteers
- 178 people
- Sponsor
- Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Colitis, Ulcerative
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)
Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system. In this study, children and teenagers with moderate to severe ulcerative colitis will be treated with vedolizumab.
- Trial name
- NCT04779307
- Testing
- Vedolizumab
- Where
- 65 sites in United States, Australia and 12 more
- Volunteers
- 121 people
- Sponsor
- Takeda